StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$46.85−0.77 (-1.62%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Enliven Therapeutics cash

Cash and short-term investments held at the end of each period.

Enliven Therapeutics's cash was $895.20M at Jun 30, 2026. For fiscal 2025 it was $462.60M, up 47.6% from the year before. The highest annual figure on record is $462.60M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$462.60M+47.6%
FY2024Dec 31, 2024$313.40M+23.8%
FY2023Dec 31, 2023$253.10M+234.8%
FY2022Dec 31, 2022$75.59M-16.3%
FY2021Dec 31, 2021$90.30M+2.4%
FY2020Dec 31, 2020$88.20M+204.2%
FY2019Dec 31, 2019$29.00M+292.8%
FY2018Dec 31, 2018$7.38M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$895.20M+82.5%
Q1 FY2026Mar 31, 2026$452.40M+56.2%
Q4 FY2025Dec 31, 2025$462.60M+47.6%
Q3 FY2025Sep 30, 2025$477.60M+63.7%
Q2 FY2025Jun 30, 2025$490.50M+57.0%
Q1 FY2025Mar 31, 2025$289.60M-9.6%
Q4 FY2024Dec 31, 2024$313.40M+23.8%
Q3 FY2024Sep 30, 2024$291.80M+10.7%
Q2 FY2024Jun 30, 2024$312.40M+12.4%
Q1 FY2024Mar 31, 2024$320.50M+9.7%
Q4 FY2023Dec 31, 2023$253.10M+234.8%
Q3 FY2023Sep 30, 2023$263.50M+368.0%
Q2 FY2023Jun 30, 2023$277.90M+360.9%
Q1 FY2023Mar 31, 2023$292.10M+300.7%
Q4 FY2022Dec 31, 2022$75.59M-16.3%
Q3 FY2022Sep 30, 2022$56.30M-45.2%
Q2 FY2022Jun 30, 2022$60.30M-9.7%
Q1 FY2022Mar 31, 2022$72.90M-3.6%
Q4 FY2021Dec 31, 2021$90.30M+2.4%
Q3 FY2021Sep 30, 2021$102.80M+7.0%
Q2 FY2021Jun 30, 2021$66.80M-37.2%
Q1 FY2021Mar 31, 2021$75.60M-28.6%
Q4 FY2020Dec 31, 2020$88.20M+204.2%
Q3 FY2020Sep 30, 2020$96.10M+462.4%
Q2 FY2020Jun 30, 2020$106.30M+135.0%
Q1 FY2020Mar 31, 2020$105.90M+116.6%
Q4 FY2019Dec 31, 2019$29.00M+292.8%
Q3 FY2019Sep 30, 2019$17.09M–
Q2 FY2019Jun 30, 2019$45.23M–
Q1 FY2019Mar 31, 2019$48.90M–
Q4 FY2018Dec 31, 2018$7.38M–

More Enliven Therapeutics figures

See a number that looks wrong?